Symptomatic care of late-onset Alexander disease presenting with area postrema-like syndrome with prednisolone; a case report.
Alexander disease
AxD type II
GFAP
Steroid
Vomiting
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
13 07 2022
13 07 2022
Historique:
received:
20
11
2021
accepted:
04
07
2022
entrez:
13
7
2022
pubmed:
14
7
2022
medline:
16
7
2022
Statut:
epublish
Résumé
Alexander disease (AxD) is classified into AxD type I (infantile) and AxD type II (juvenile and adult form). We aimed to determine the potential genetic cause(s) contributing to the AxD type II manifestations in a 9-year-old male who presented area postrema-like syndrome and his vomiting and weight loss improved after taking prednisolone. A normal cognitive 9-year-old boy with persistent nausea, vomiting, and a significant weight loss at the age of 6 years was noticed. He also experienced an episode of status epilepticus with generalized atonic seizures. He showed non-febrile infrequent multifocal motor seizures at the age of 40 days which were treated with phenobarbital. He exhibited normal physical growth and neurologic developmental milestones by the age of six. Occasionally vomiting unrelated to feeding was reported. Upon examination at 9 years, a weak gag reflex, prominent drooling, exaggerated knee-deep tendon reflexes (3+), and nasal tone speech was detected. All gastroenterological, biochemical, and metabolic assessments were normal. Brain magnetic resonance imaging (MRI) revealed bifrontal confluent deep and periventricular white matter signal changes, fine symmetric frontal white matter and bilateral caudate nucleus involvements with garland changes, and a hyperintense tumefactive-like lesion in the brain stem around the floor of the fourth ventricle and area postrema with contrast uptake in post-contrast T1-W images. Latter MRI at the age of 8 years showed enlarged area postrema lesion and bilateral middle cerebellar peduncles and dentate nuclei involvements. Due to clinical and genetic heterogeneities, whole-exome sequencing was performed and the candidate variant was confirmed by Sanger sequencing. A de novo heterozygous mutation, NM_001242376.1:c.262 C > T;R88C in exon 1 of the GFAP (OMIM: 137,780) was verified. Because of persistent vomiting and weight loss of 6.0 kg, prednisolone was prescribed which brought about ceasing vomiting and led to weight gaining of 3.0 kg over the next 3 months after treatment. Occasional attempts to discontinue prednisolone had been resulting in the reappearance of vomiting. This study broadens the spectrum of symptomatic treatment in leukodystrophies and also shows that R88C mutation may lead to a broad range of phenotypes in AxD type II patients.
Sections du résumé
BACKGROUND
Alexander disease (AxD) is classified into AxD type I (infantile) and AxD type II (juvenile and adult form). We aimed to determine the potential genetic cause(s) contributing to the AxD type II manifestations in a 9-year-old male who presented area postrema-like syndrome and his vomiting and weight loss improved after taking prednisolone.
CASE PRESENTATION
A normal cognitive 9-year-old boy with persistent nausea, vomiting, and a significant weight loss at the age of 6 years was noticed. He also experienced an episode of status epilepticus with generalized atonic seizures. He showed non-febrile infrequent multifocal motor seizures at the age of 40 days which were treated with phenobarbital. He exhibited normal physical growth and neurologic developmental milestones by the age of six. Occasionally vomiting unrelated to feeding was reported. Upon examination at 9 years, a weak gag reflex, prominent drooling, exaggerated knee-deep tendon reflexes (3+), and nasal tone speech was detected. All gastroenterological, biochemical, and metabolic assessments were normal. Brain magnetic resonance imaging (MRI) revealed bifrontal confluent deep and periventricular white matter signal changes, fine symmetric frontal white matter and bilateral caudate nucleus involvements with garland changes, and a hyperintense tumefactive-like lesion in the brain stem around the floor of the fourth ventricle and area postrema with contrast uptake in post-contrast T1-W images. Latter MRI at the age of 8 years showed enlarged area postrema lesion and bilateral middle cerebellar peduncles and dentate nuclei involvements. Due to clinical and genetic heterogeneities, whole-exome sequencing was performed and the candidate variant was confirmed by Sanger sequencing. A de novo heterozygous mutation, NM_001242376.1:c.262 C > T;R88C in exon 1 of the GFAP (OMIM: 137,780) was verified. Because of persistent vomiting and weight loss of 6.0 kg, prednisolone was prescribed which brought about ceasing vomiting and led to weight gaining of 3.0 kg over the next 3 months after treatment. Occasional attempts to discontinue prednisolone had been resulting in the reappearance of vomiting.
CONCLUSIONS
This study broadens the spectrum of symptomatic treatment in leukodystrophies and also shows that R88C mutation may lead to a broad range of phenotypes in AxD type II patients.
Identifiants
pubmed: 35831840
doi: 10.1186/s12887-022-03468-y
pii: 10.1186/s12887-022-03468-y
pmc: PMC9277918
doi:
Substances chimiques
Glial Fibrillary Acidic Protein
0
Prednisolone
9PHQ9Y1OLM
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
412Informations de copyright
© 2022. The Author(s).
Références
Iran J Pediatr. 2013 Aug;23(4):481-4
pubmed: 24427505
Neurology. 2011 Sep 27;77(13):1287-94
pubmed: 21917775
Neurotherapeutics. 2010 Oct;7(4):507-15
pubmed: 20880512
Ann Neurol. 2005 Mar;57(3):310-26
pubmed: 15732097
Mol Biol Cell. 2016 Dec 15;27(25):3980-3990
pubmed: 27798231
AJNR Am J Neuroradiol. 2001 Mar;22(3):541-52
pubmed: 11237983
Eur J Med Genet. 2020 Dec;63(12):104096
pubmed: 33186761
J Cell Sci. 2014 Oct 15;127(Pt 20):4368-80
pubmed: 25128567
Brain Dev. 2020 Jan;42(1):64-68
pubmed: 31455510
Acta Neuropathol. 2015 Oct;130(4):469-86
pubmed: 26296699
Am J Hum Genet. 2001 Nov;69(5):1134-40
pubmed: 11567214
Balkan J Med Genet. 2019 Dec 21;22(2):77-82
pubmed: 31942421
Eur J Hum Genet. 2016 Jun;24(6):852-6
pubmed: 26486469
J Child Neurol. 2008 Feb;23(2):173-7
pubmed: 18079314
J Hum Genet. 2013 Apr;58(4):183-8
pubmed: 23364391
J Hum Genet. 2007;52(4):362-369
pubmed: 17318298
Neurology. 2021 Sep 14;97(11):548-549
pubmed: 34233935
Curr Opin Cell Biol. 2015 Feb;32:121-30
pubmed: 25726916
Neurology. 2015 Jan 20;84(3):226-30
pubmed: 25527264
Expert Rev Neurother. 2020 Jan;20(1):65-84
pubmed: 31829048